Last updated: 2026-10-13 22:23:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
TransMedics Group, Inc. (TMDX) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $79.11, with a market capitalization of $2.70B and a P/E ratio of 17.87. Over the past 52 weeks, its price has ranged from $60.11 to $156.00. This page covers its latest market performance, valuation, price trends and company information.
$2.70B | |
$78.17 | |
$177.37 | |
$10.00 | |
$78.17 | |
892.57K | |
813.63K | |
17.87 | |
$156.00 | |
$60.11 | |
-- | |
-- |
TransMedics Group, Inc. (TMDX) is trading at $79.00 in after-hours trading as of 2026-10-13 20:43:00, up 1.06% ($0.83) from the regular-session close of $78.17.
After-hours trading shows how investors are pricing TMDX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, TransMedics Group, Inc. (TMDX) moved from $79.80 to $79.11, representing a decline of 0.85% ($0.68).
The stock traded between $76.86 and $84.05 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 846.79 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.8%
TMDX is currently trading at $79.11, placing it 19.8% of the way from its 52-week low of $60.11 to its 52-week high of $156.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 898 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransMedics Group, Inc. (TMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.